LumiraDx receives $14m in funding for point-of-care TB test
December 15, 2022Medical Communications
UK-based point-of-care diagnostics company LumiraDx has been given $14m in grants from the Bill & Melinda Gates Foundation to support …
New drug application for AstraZeneca’s Lynparza given more time by FDA
December 15, 2022Medical Communications
AstraZeneca and its US collaborator, Merck, have announced that the FDA is allowing more time for the review of the …
FlyPharma Conference Middle East: New location announced
December 14, 2022Business Services
FlyPharma Conferences are pleased to announce an exciting new addition to its event portfolio: FlyPharma Middle East. Taking place in …
David Brocklehurst
December 14, 2022Business Services
London, UK, 12 December 2022 – AstraZeneca UK announces the appointment of David Brocklehurst as Head of Oncology in the …
Merck and Moderna’s mRNA cancer vaccine is successful in efficacy trial
December 14, 2022Research and Development
Merck & Co and Moderna have partnered to utilise the mRNA technology used to combat COVID-19, however this time the …
ClearPoint recruits first patient in laser therapy study to treat Glioblastoma
December 14, 2022Research and Development
California, US-based ClearPoint Neuro has recruited the first patient in a clinical trial which will use ClearPoint’s Prism Neuro Laser …
AI model predicts CVD risk from single chest radiograph
December 14, 2022Research and Development
A recently-developed AI model has been shown to predict ten-year incidences with a similar level of success to the current …
GlaxoSmithKline enter into $3.3bn pact with Wave Life Sciences over oligonucleotides
December 14, 2022Medical Communications
UK-based GSK has announced a partnership with American company Wave Life Sciences, valued at up to $3.3bn. The partnership will …
GSK chooses London’s West End for new headquarters
December 13, 2022Medical Communications
GlaxoSmithKline has chosen to establish its new headquarters in London’s West End, on the corner of New Oxford Street and …
Autolus announces positive primary endpoint data in FELIX trial
December 13, 2022Research and Development
Autolus Therapeutic, a clinical-stage biopharmaceutical company, has announced that the phase 2 FELIX clinical trial of obecabtagene autoleucel (obe-cel) in …
Seagen shares data for Adcetris combination for Hodgkin Lymphoma
December 13, 2022Research and Development
Adcetris has long been one of Seagen’s top-selling and expanding products, and it has announced that the drug appeared successful …
RemeGen’s RC118 granted two orphan drug designations by FDA
December 13, 2022Medical Communications
Chinese commercial-stage biotechnology company RemeGen has announced that RC118 for injection – its latest antibody-drug conjugate (ADC) – has been …
New blood cancer treatment appears successful for most trial patients
December 12, 2022Research and Development
A new and experimental immunotherapy treatment has appeared successful in treating patients with multiple myeloma in an ongoing phase 1/2 …
Amgen expected to buy Horizon at valuation of $26bn
December 12, 2022Sales and Marketing
Amgen Inc is expected to acquire biotech firm Horizon Therapeutics Plc at a valuation of $26bn. This would be Amgen’s …
UK Strep A death toll rises to 15
December 9, 2022Medical Communications
Data from the UK Health Security Agency (UKHSA) show that 15 children under the age of 15 have now died …
FDA priority review given to Pfizer’s RSV vaccine for older adults
December 9, 2022Medical Communications
Pfizer has announced that the FDA has accepted its application for a respiratory syncytial virus (RSV) vaccine for older adults, …
Biocorp receives FDA 510(k) approval for Mallya device
December 8, 2022Medical Communications
French medical devices company, Biocorp, has received the FDA’s 510(k) approval for diabetes care device, Mallya. The device is a …
Novartis and MorphoSys sign $23m deal
December 8, 2022Sales and Marketing
MorphoSys has announced that it will sell its worldwide licensing rights to its preclinical cancer programme to Novartis in exchange …
AbbVie to enter deal with HotSpot for up to $335m
December 7, 2022Sales and Marketing
AbbVie and HotSpot Therapeutics have begun working on a licensing option deal for HotSpot’s preclinical small-molecule allosteric therapy, which will …
EMA accepts marketing authorisation application for ALS treatment, tofersen
December 7, 2022Sales and Marketing
The European Medicines Agency (EMA) has accepted a marketing authorisation application (MAA) for tofersen. The drug would treat superoxide dismutase …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
